They divided it into two subgroups according to the mutation profile—endometrioid-carcinoma-like (frequent PTEN, ARID1A, PIK3R1, and POLE mutations) and serous-carcinoma-like (TP53, PPP2R1A, EP300, and FBXW7 mutations) [9]. This evidence concerns the gene PTEN and endometrioid adenocarcinoma.